ArticlePharmaceutical biology2017
The novel role of β-aescin in attenuating CCl
Article in Pharmaceutical biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 17 citations in OpenAlex.
- Analysis of the Anti-Inflammatory and Anti-Osteoarthritic Potential of Flonat FastPharmaceuticals (Basel, Switzerland) · 2022Article
- Potential protective effect of escin fromToxicology research · 2022Article
- The role of Neu1 in the protective effect of dipsacoside B on acetaminophen-induced liver injury.Annals of translational medicine · 2020Article
- Aescin and diosmin each alone or in low dose- combination ameliorate liver damage induced by carbon tetrachloride in rats.BMC research notes · 2020Article
- Escin protects against acetaminophen-induced liver injury in mice via attenuating inflammatory response and inhibiting ERK signaling pathway.American journal of translational research · 2019Article
- Protective effect of dexpanthenol against cisplatin-induced hepatotoxicity.Experimental and therapeutic medicine · 2018Article
- Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study.Clinical rheumatology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextβ-Aescin has anti-inflammatory, anti-oxidant and antiedematous properties.
objectiveThe present study investigated the hepatoprotective effect and underlying mechanisms of β-aescin in CCl MATERIALS AND
methodsThirty-five Wistar rats were divided into six groups: normal control, CCl
resultsβ-Aescin (3.6 mg/kg) markedly decreased CCl DISCUSSION AND
conclusionThe findings suggest that β-aescin has a protective effect on CCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.